argenx SE

Regulatory Filings • Mar 13, 2015

arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

Breda, the Netherlands / Ghent, Belgium, 13 March 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.

The presentation will be webcast live and may be accessed by visiting the 'News & events' section of the Company's website at www.argen-x.com. A replay of this webcast will be available for 90 days following the presentation.

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a pipeline of differentiated clinical and preclinical antibody candidates using its SIMPLE Antibody(TM) discovery platform. SIMPLE Antibody(TM) has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Proprietary Fc engineering technologies (NHance® and ABDEG(TM)) and POTELLIGENT® technology (licensed from BioWa, Inc.) further enhance the therapeutic properties of SIMPLE Antibody(TM) leads in terms of tissue penetration/residence time in the body, ability to clear disease targets or pathogenic antibodies and cell-killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.

www.arGEN-X.com

SIMPLE Antibody(TM), NHance® and ABDEG(TM) are trademarks of arGEN-X NV POTELLIGENT® is a trademark of BioWa Inc.

For further information, please contact:

Joke Comijn, Corporate Communications Manager +32 (0)9 243 40 70 info@arGEN-X.com

Mark Swallow/David Dible Citigate Dewe Rogerson +44 207 282 2948 arGEN-X@citigatedr.co.uk

Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200 beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X' actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.